Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 5/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17796981 | 0.88 | CHRM3 (0.56) | CHRM3OPRD1KMT2ACHRNB2CHRNB4 | |
| SCHEMBL17797022 | 0.86 | CHRM3 (0.52) | CHRM3CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL17797012 | 0.86 | CHRM3 (0.52) | CHRM3CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL17796972 | 0.83 | CHRM3 (0.54) | CHRM3OPRD1KMT2AKDM2BCHRNB2 | |
| SCHEMBL17840987 | 0.79 | CHRM3 (0.54) | CHRM3SMN1; SMN2KMT2ACHRNB2CHRNB4 | |
| SCHEMBL17840986 | 0.79 | CHRM3 (0.54) | CHRM3SMN1; SMN2KMT2ACHRNB2CHRNB4 | |
| SCHEMBL17840162 | 0.79 | CHRM3 (0.54) | CHRM3HCRTR1HCRTR2 | |
| SCHEMBL17840164 | 0.79 | CHRM3 (0.54) | CHRM3HCRTR1HCRTR2 | |
| SCHEMBL17839984 | 0.77 | CHRM3 (0.56) | CHRM3CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL17840312 | 0.77 | CHRM3 (0.56) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3029026-B1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | DONG A ST CO LTD (KR) | 2018-12-05 | — | — | EP | claimed |
| US-9828339-B2 | Biphenyl derivatives and methods for preparing same | DONG-A ST CO., LTD (KR) | 2017-11-28 | — | — | US | claimed |
| US-20160176816-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | DONG-A ST CO., LTD (KR) | 2016-06-23 | — | — | US | claimed |
| EP-3029026-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | Dong-A ST Co., Ltd. (KR) | 2016-06-08 | — | — | EP | claimed |
| EP-3029026-B1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | DONG A ST CO LTD (KR) | 2018-12-05 | — | — | EP | disclosed |
| US-9828339-B2 | Biphenyl derivatives and methods for preparing same | DONG-A ST CO., LTD (KR) | 2017-11-28 | — | — | US | disclosed |
| US-20160176816-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | DONG-A ST CO., LTD (KR) | 2016-06-23 | — | — | US | disclosed |
| EP-3029026-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | Dong-A ST Co., Ltd. (KR) | 2016-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176816-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | CHRM2, CHRM3, CHRM5 | CHRM3 2/4885OPRD1 386/4885RAB9A 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.